In October 2026 the CHMP did not recommend extending Mylotarg (gemtuzumab ozogamicin) to children aged 1 to under 18 with newly diagnosed AML. Even so, relevant study data are to be added to the product information. The outcome illustrates how paediatric data can matter without an indication.
Two separate questions
Whether a medicine is indicated in children and whether paediatric study results appear in the product information are distinct issues. The CHMP can decline an indication while still concluding that the data deserve a place in the summary of product characteristics, so prescribers understand what is and is not known.
The role of Article 46
Under Article 46 of the Paediatric Regulation (EC) No 1901/2006, results of paediatric studies on authorised products must be submitted to the competent authorities within six months of completion, whether or not the studies support a paediatric indication. Assessors then decide what should be reflected in the product information.
Practical consequences
- Labelling updates follow the data. Section 4.2 and section 5.1 are the usual places for paediatric posology and results.
- National alignment. Updated texts need to be implemented in each market, including Greece, within the required timelines.
- Safety communication. Information from children may affect the risk management plan and pharmacovigilance activities.
Planning paediatric work
Paediatric investigation plans should be tracked as lifecycle commitments. Missed submission deadlines for study results are a recurring compliance finding and can complicate later regulatory steps.
How PQRA helps
PQRA tracks PIP milestones, prepares Article 46 submissions and coordinates product information updates across procedures, so paediatric obligations do not become a late compliance problem.


No responses yet